TABLE 3.

Association of ncRNA polymorphisms with prognosis of patients with lung cancer (n = 446).

			OS			PFS
Gene/SNP	Genotype/Genetic model	MST (month)	HR (95% CI)	P Value	MST (month)	HR (95% CI)	P Value
miR-146A	CC	28.8	1.00	—	10.3	1.00	—
rs2910164	CG	36.3	0.78 (0.63–0.97)	0.023*	14.1	0.82 (0.67–1.01)	0.062
	GG	32.5	0.91 (0.66–1.26)	0.569	13.9	0.78 (0.57–1.08)	0.130
	Additive	32.5/36.3/28.8	0.90 (0.77–1.05)	0.162	13.9/14.1/10.3	0.86 (0.74–1.00)	0.053
	Dominant	35.6/28.8	0.81 (0.66–0.99)	0.036*	14.1/10.3	0.81 (0.67–0.99)	0.040*
	Recessive	32.5/31.7	1.05 (0.78–1.42)	0.757	13.9/11.7	0.88 (0.65–1.18)	0.384
miR-378A	GG	36.1	1.00	—	11.1	1.00	—
rs1076064	GA	29.2	1.32 (1.03–1.69)	0.026*	11.4	1.04 (0.81–1.32)	0.783
	AA	37.1	0.99 (0.73–1.33)	0.920	16.2	0.89 (0.66–1.19)	0.423
	Additive	37.1/29.2/36.1	1.00 (0.87–1.15)	0.992	16.2/11.4/11.1	0.94 (0.81–1.09)	0.420
	Dominant	30.1	1.21 (0.96–1.54)	0.109	12.7	0.99 (0.78–1.25)	0.927
	Recessive	30.6	0.81 (0.63–1.04)	0.101	11.1	0.86 (0.68–1.10)	0.233
ANRIL	GG	33.5	1.00	—	10.1	1.00	—
rs1333049	GC	28.3	1.14 (0.89–1.46)	0.311	11.7	0.90 (0.71–1.15)	0.413
	CC	37.4	0.88 (0.65–1.18)	0.393	14.5	0.71 (0.53–0.96)	0.023*
	Additive	37.4/28.3/33.5	0.94 (0.81–1.08)	0.356	14.5/11.7/10.1	0.84 (0.73–0.97)	0.021*
	Dominant	32.1/33.5	1.05 (0.83–1.33)	0.700	12.7/10.1	0.84 (0.66–1.06)	0.148
	Recessive	37.4/29.5	0.80 (0.63–1.02)	0.068	14.45/11.1	0.77 (0.61–0.97)	0.026*

OS, overall survival; PFS, progression-free survival; MST, median survival time; HR, hazard ratio; CI, confidence interval; *p < 0.05.